FACE-OFF: Team Blue vs Team Purple
Amer Zeidan, MBBS; Catherine Lai, MD; Bart Scott, MD; Andrew Brunner, MD; Jonathan Abbas, MD; Akriti Jain, MD; Mohamed Hegazi, MD; Somedeb Ball, MBBS; and Salman Fazal, MD, examine critical clinical decisions in myelodysplastic syndrome management, including optimal sequencing of erythropoiesis-stimulating agents vs luspatercept, dosing strategies, and efficacy data from pivotal trials such as MEDALIST, IMerge, and ELEMENT-MDS, which demonstrate improvements in transfusion burden and hemoglobin levels.
EP. 4: Do We Start Luspatercept at the Highest Dose and Titrate Down or Start Low and Titrate Up?
January 13th 2025Panelists discuss how to optimize luspatercept dosing strategies by evaluating the benefits and risks of starting at maximum dose with downward titration vs initiating at lower doses with upward adjustments.
